Genetics of systemic sclerosis-associated pulmonary arterial hypertension: Recent progress and current concepts

被引：0

作者：

Shah S.J. ^{[1
]}

机构：

[1] Center for Heart Failure, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611

来源：

Current Rheumatology Reports | 2009年 / 11卷 / 2期

关键词：

Pulmonary Hypertension; Pulmonary Arterial Hypertension; Systemic Sclerosis; Connective Tissue Disease; Hereditary Hemorrhagic Telangiectasia;

D O I：

10.1007/s11926-009-0013-5

中图分类号：

学科分类号：

摘要：

Pulmonary arterial hypertension (PAH) is a devastating complication of systemic sclerosis (SSc). Although there are screening tests for PAH, such as carbon monoxide diffusing capacity and Doppler echocardiography, these tests are far from perfect, patients are still identified late in the course of disease, and the underlying mechanisms of SSc-associated PAH are poorly understood. Understanding the genetic differences between those patients with SSc who do and do not develop PAH may improve our ability to identify and treat patients earlier in the course of disease. To date, only a few candidate gene association studies and one gene expression analysis have investigated the genetics of PAH in SSc. These studies highlight the important opportunities and challenges for exploration of genetics of complex traits. By appreciating the optimal conduct of genetic studies, along with the role of bioinformatics resources such as the International HapMap database, investigators and clinicians will be better equipped to understand the genetics of SSc-associated PAH. © 2009 Current Medicine Group, LLC.

引用

页码：89 / 96

页数：7

共 51 条

[1]

Rubin L.J., Badesch D.B., Evaluation and management of the patient with pulmonary arterial hypertension, Ann Intern Med, 143, pp. 282-292, (2005)

[2]

Rubin L.J., Introduction. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines, Chest, 126, 1 SUPPL., (2004)

[3]

Proceedings of the 3rd World Symposium on Pulmonary Arterial Hypertension, (2003)

[4]

J Am Coll Cardiol, 43, (2004)

[5]

Ramirez A., Varga J., Pulmonary arterial hypertension in systemic sclerosis: Clinical manifestations, pathophysiology, evaluation, and management, Treat Respir Med, 3, pp. 339-352, (2004)

[6]

Varga J., Pulmonary hypertension in systemic sclerosis: Bete noire no more?, Current Opinion in Rheumatology, 14, 6, pp. 666-670, (2002)

[7]

MacGregor A.J., Canavan R., Knight C., Et al., Pulmonary hypertension in systemic sclerosis: Risk factors for progression and consequences for survival, Rheumatology (Oxford), 40, pp. 453-459, (2001)

[8]

Kawut S.M., Taichman D.B., Archer-Chicko C.L., Palevsky H.I., Kimmel S.E., Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis, Chest, 123, 2, pp. 344-350, (2003)

[9]

Mukerjee D., St George D., Coleiro B., Knight C., Denton C.P., Davar J., Black C.M., Coghlan J.G., Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: Application of a registry approach, Annals of the Rheumatic Diseases, 62, 11, pp. 1088-1093, (2003)

[10]

Thenappan T., Shah S.J., Rich S., Gomberg-Maitland M., A USA-based registry for pulmonary arterial hypertension: 1982-2006, European Respiratory Journal, 30, 6, pp. 1103-1110, (2007)

← 1 2 3 4 5 6 →